Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CHKA | P35790 | 1/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3713084 | 0.83 | CA2 (0.45) | CA2CHKATRPV4LOXL2LOX | |
| SCHEMBL17949359 | 0.80 | TRPV4 (0.41) | CA2CHKATRPV4LOXL2LOX | |
| SCHEMBL29679747 | 0.80 | CA2 (0.50) | CA2CHKATRPV4LOXL2LOX | |
| SCHEMBL3037202 | 0.80 | CA2 (0.50) | CA2CHKATRPV4LOXL2LOX | |
| SCHEMBL24228137 | 0.77 | CA2 (0.47) | CA2CHKATRPV4LOXL2LOX | |
| SCHEMBL30340741 | 0.77 | TRPV4 (0.39) | CA2CHKATRPV4LOXL2LOX | |
| SCHEMBL17801322 | 0.77 | CA2 (0.47) | CA2CHKATRPV4LOXL2LOX | |
| SCHEMBL29002089 | 0.77 | TRPV4 (0.39) | CA2CHKATRPV4LOXL2LOX | |
| SCHEMBL30722292 | 0.77 | CA2 (0.47) | CA2CHKATRPV4LOXL2LOX | |
| SCHEMBL1506481 | 0.75 | UHRF1 (0.54) | CA2CHKATRPV4LOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618977-A1 | LRRK2 INHIBITORS AND USES THEREOF | Neuron23, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20240228493-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240208972-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024108128-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024108116-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-10420753-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| US-10420753-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-09-24 | — | — | US | disclosed |
| EP-3419981-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | Indiana University Research & Technology Corporation (US) | 2019-01-02 | — | — | EP | disclosed |
| US-20180235943-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-08-23 | — | — | US | disclosed |
| US-9895358-B2 | Combination therapies for treatment of spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170239225-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-08-24 | — | — | US | disclosed |
| EP-2521727-B1 | NEW BENZOIC PYRROLOPYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PARKINSON'S DISEASE | INVENTIVA (FR) | 2014-03-19 | — | — | EP | disclosed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | disclosed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | disclosed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | disclosed |
| EP-2521727-A1 | NOVEL BENZOIC PYRROLOPYRIDINE DERIVATIVES | Laboratoires Fournier S.A. (FR) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011083278-A1 | NOVEL BENZOIC PYRROLOPYRIDINE DERIVATIVES | LABORATOIRES FOURNIER SA (FR) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235943-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYOF | CA2 4277/4885CHKA 2064/4885TRPV4 4692/4885 |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | NCOR1, NCOR2, NR0B1 | CA2 3869/4885CHKA 3637/4885TRPV4 1845/4885 |
| US-10420753-B2 | Combination therapies for treatment of spinal muscular atrophy | SMN1; SMN2, MUSK, MYOF | CA2 4277/4885CHKA 2064/4885TRPV4 4692/4885 |
| US-20240208972-A1 | LRRK2 INHIBITORS AND USES THEREOF | LRRK2, PINK1, PARK7 | CA2 4682/4885CHKA 510/4885TRPV4 3814/4885 |
| US-20170239225-A1 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYOF | CA2 4277/4885CHKA 2064/4885TRPV4 4692/4885 |
| US-20240228493-A1 | LRRK2 INHIBITORS AND USES THEREOF | LRRK2, PINK1, PARK7 | CA2 4682/4885CHKA 510/4885TRPV4 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.